Warner Greene, MD, PhD

Headshot of Warner Greene
User Profile Photo

Warner Greene, MD, PhD

User Profile Name
Director, Gladstone Center for HIV Cure Research
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science. He also serves as Co-Director of the UCSF-Gladstone Center for AIDS Research, and has served as a Councilor and President of the Association of American Physicians. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as the Founding Director of the Gladstone Institute of Virology and Immunology in 1991. The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying HIV pathogenesis, latency, and transmission. He is the author of more than 380 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. In 2007, Dr. Greene expanded his work to include global health in sub-Saharan Africa in his service as president and executive chairman of the Accordia Global Health Foundation. Accordia established the Infectious Diseases Institute at Makerere University in Uganda, which has trained thousands of African health care workers, is caring for 30,000 HIV-infected patients, and has brought health care to nearly 500,000 people living in remote rural regions of Uganda. In 2016, Accordia merged with Africare.
CTSI Profile Bio

Displaying 76 - 100 of 386

  1. Wissing S, Muñoz-Lopez M, Macia A, Yang Z, Montano M, Collins W, Garcia-Perez JL, Moran JV, Greene WC. Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. Hum Mol Genet. 2012 Jan 01; 21(1):208-18.
  2. Smith DS, Guo K, Barrett BS, Heilman KJ, Evans LH, Hasenkrug KJ, Greene WC, Santiago ML. Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog. 2011 Oct; 7(10):e1002284.
  3. Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a007096.
  4. Wissing S, Montano M, Garcia-Perez JL, Moran JV, Greene WC. Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem. 2011 Oct 21; 286(42):36427-37.
  5. Sakane N, Kwon HS, Pagans S, Kaehlcke K, Mizusawa Y, Kamada M, Lassen KG, Chan J, Greene WC, Schnoelzer M, Ott M. Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog. 2011 Aug; 7(8):e1002184.
  6. Chan JK, Greene WC. NF-?B/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS. 2011 Jan; 6(1):12-8.
  7. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, Hebbeler AM, Greene WC. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010 Nov 24; 143(5):789-801.
  8. Challacombe SJ, Fidel PL, Tugizov S, Tao L, Wahl SM. HIV infection and specific mucosal immunity: workshop 4B. Adv Dent Res. 2011 Apr; 23(1):142-51.
  9. Santiago ML, Smith DS, Barrett BS, Montano M, Benitez RL, Pelanda R, Hasenkrug KJ, Greene WC. Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol. 2011 Jan; 85(1):189-99.
  10. Lassen KG, Wissing S, Lobritz MA, Santiago M, Greene WC. Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. J Biol Chem. 2010 Sep 17; 285(38):29326-35.
  11. Kim KA, Yolamanova M, Zirafi O, Roan NR, Staendker L, Forssmann WG, Burgener A, Dejucq-Rainsford N, Hahn BH, Shaw GM, Greene WC, Kirchhoff F, Münch J. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology. 2010 Jun 23; 7:55.
  12. Santiago ML, Benitez RL, Montano M, Hasenkrug KJ, Greene WC. Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol. 2010 Jul 15; 185(2):1114-23.
  13. Wissing S, Galloway NL, Greene WC. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med. 2010 Oct; 31(5):383-97.
  14. Cavrois M, Neidleman J, Galloway N, Derdeyn CA, Hunter E, Greene WC. Measuring HIV fusion mediated by envelopes from primary viral isolates. Methods. 2011 Jan; 53(1):34-8.
  15. Roan NR, Sowinski S, Münch J, Kirchhoff F, Greene WC. Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem. 2010 Jan 15; 285(3):1861-9.
  16. Chiu YL, Greene WC. APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12; 364(1517):689-703.
  17. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009 Mar 06; 323(5919):1304-7.
  18. Michel N, Goffinet C, Ganter K, Allespach I, Kewalramani VN, Saifuddin M, Littman DR, Greene WC, Goldsmith MA, Keppler OT. Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. Retrovirology. 2009 Jan 13; 6:2.
  19. Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D. Unsung hero Robert C. Gallo. Science. 2009 Jan 09; 323(5911):206-7.
  20. LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jónsson SR, Landau NR, Löchelt M, Malik HS, Malim MH, Münk C, O'Brien SJ, Pathak VK, Strebel K, Wain-Hobson S, Yu XF, Yuhki N, Harris RS. Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol. 2009 Jan; 83(2):494-7.
  21. Roan NR, Münch J, Arhel N, Mothes W, Neidleman J, Kobayashi A, Smith-McCune K, Kirchhoff F, Greene WC. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol. 2009 Jan; 83(1):73-80.
  22. Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W, Buckheit RW, Esté JA, Cihlar T. Novel targets for HIV therapy. Antiviral Res. 2008 Dec; 80(3):251-65.
  23. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science. 2008 Sep 05; 321(5894):1343-6.
  24. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. HIV vaccine research: the way forward. Science. 2008 Jul 25; 321(5888):530-2.
  25. Cavrois M, Neidleman J, Greene WC. The achilles heel of the trojan horse model of HIV-1 trans-infection. PLoS Pathog. 2008 Jun 27; 4(6):e1000051.